



Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference

September 2, 2026

CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.

A live webcast of the fireside chat will be available [here](#) and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following each presentation.

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC[®] gene targeted chimera small molecules. The company's GeneTAC[®] molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC[®] programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington's disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:

Renee Leck, THRUST
renee@thrustsc.com